Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12551114 | 0.58 | KDM4E (0.59) | KDM4E | |
| SCHEMBL21855601 | 0.58 | CNR2 (0.33) | KDM4E | |
| SCHEMBL25488838 | 0.56 | CNR2 (0.36) | KDM4E | |
| SCHEMBL21738073 | 0.56 | GAA (0.36) | KDM4E | |
| SCHEMBL5106395 | 0.55 | KDM4E (0.36) | KDM4E | |
| SCHEMBL1830206 | 0.55 | KDM4E (0.38) | KDM4E | |
| SCHEMBL1032563 | 0.54 | KDM4E (0.55) | KDM4E | |
| SCHEMBL15985155 | 0.54 | — | — | |
| SCHEMBL349943 | 0.54 | — | — | |
| SCHEMBL31178490 | 0.54 | KDM4E (0.38) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050069541-A1 | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050069541-A1 | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents | MAG, PMP22, GAP43 | KDM4E 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.